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Abstract
The CERERRA database provides evidence that low-dose rituximab performs as well as the conventional dose in the
real world, thus highlighting the possible pharmacoeconomic impact. In clinical trials, it has been shown that
rituximab 500 mg twice, performs as well as 1 g twice, 2 weeks apart, in terms of the American College of Rheumatology
(ACR)20 and ACR50, but not the ACR70. The choice should always be made after considering that the IMAGE trial has
demonstrated similar radiographic progression after the first 6 months, but with less control, with low-dose rituximab in
the first 6 months. A possible alternative can be hypothesized.
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Editorial
One of the personalized approaches to rheumatoid
arthritis (RA) has been obtained with rituximab. Since
inception it has been observed that RA patients
treated with rituximab, positive for rheumatoid factor
(RF) or anti-cyclic citrullinated peptide autoantibodies
(ACPA), obtained more clinical benefits than sero-
negative patients [1–3].
The rationale for using B-cell depletion was based on
the idea that RA is the consequence of a failure of B-cell
death in the synovium [4].
Whether peripheral blood B-cell depletion means the
same as tissue depletion is debatable. In one patient with
idiopathic thrombocytopenic purpura, no B cells were
seen in the peripheral blood or in the bone marrow or
the spleen 3 months after the final rituximab infusion
(375 mg/m2 weekly for 4 weeks) [5]. Looking more
closely at RA, however, there is synovial tissue evidence
that, after 4 weeks following rituximab infusion (1 g
twice, 2 weeks apart), all of 17 biopsied patients had
peripheral B-cell depletion, yet only in three patients
had B cells disappeared from the synovial tissue. There-
fore rituximab was only partially effective in depleting B
cells in the majority of the synovial tissues [6]. Whether
the lack of B-cell depletion in the tissue depends on the
interval between rituximab infusion and tissue analysis
being too short, or because tissue depletion is really vari-
able, even more so at different dosages, is not known.
Accordingly, we need to rely almost exclusively on trials
or registries to select the doses.
In clinical trials the 500 mg twice dose gave similar re-
sults to the 1 g twice dose when measuring the Ameri-
can College of Rheumatology 20 % improvement
(ACR20) and ACR50 responses, but not for the major
outcomes of ACR70 and Good EULAR response [7]. In
the MIRROR trial, the high dose performed better [8].
In the study by Chatzidionysiou et al. [1] the authors ex-
amined the clinical response to two doses of rituximab
(low dose (LD), 500 mg twice; and conventional dose
(SD), 1 g twice) in more than 2800 patients with RA
from 12 countries. The two cohorts differ at baseline for
several factors, but the three most relevant for the out-
come after rituximab were the number of patients (LD
n = 248 vs CD n = 2625), disease activity (DAS-ESR28)
and health assessment questionnaire (HAQ) levels being
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lower with the LD schedule, and in the percentage of pa-
tients who received previous tumor necrosis factor
(TNF) blockers being higher with the LD schedule [1].
It is well known that the lower the level of disease ac-
tivity, the higher is the percentage of success in terms of
low-disease activity (LDA) or disease remission (DR).
Moreover, the chance of obtaining LDA or DR is higher
for the first biologic than for the second or third biologic
[9]. Yet, in this study the delta of improvement was sig-
nificantly better in the CD cohort, even though the trend
suggested that, the longer the observation period, the
lower the difference between the two dosages. Overall
the main conclusion was that there was “evidence about
the lack of any striking difference and perhaps no clinic-
ally significant difference between two different doses of
rituximab used in clinical practice”.
The Authors recognize that the lack of radiographic
data do not allow us to definitely state that the doses are
similarly effective from all viewpoints. In fact, the
IMAGE trial [10] showed a lower effectiveness of the LD
using radiographic damage in the first 6 months, this be-
ing similar to the control of structural progression in the
second 6 months.
In the study of Chatzidyonisiou et al. improvements
were already present after 3 months, suggesting that a
tight control of the outcomes following a treat-to-target
strategy (major clinical assessment every 3 months) is
possible in real life at both dosages. Given that similar
results were seen after 3 months, as well as after
6 months, in a treat-to-target strategy the CD would
very likely offer much more certainty of a result.
In conclusion, this study shows that in active, long
standing RA with functional impairment, a LD sched-
ule of rituximab gives 6-month follow-up clinical re-
sults similar to those obtained with CD, but the data
have to be interpreted in the absence of radiographic
analysis. The lack of a long-term assessment makes
any possible choice in terms of clinical practice diffi-
cult because we have no idea when the LD schedule
would lead us to re-treat patients when compared to
the CD.
The most important message relies on the possible
pharmacoeconomic consequences. The real clue, not
proven by the data available here however, could be the
possible third choice, demonstrated to be realistic by
Mariette et al. [11]: first infusion with the CD schedule
and, in cases with good response (DR or LDA), the LD
schedule for the re-treatments. This would really allow
us to save a lot of money (Fig. 1).
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